Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: John Romeo who wrote (5490)	10/13/1998 6:07:00 AM
From: nord	Read Replies (3) \| Respond to of 6136

re earnings Ihave heard that sales and earnings are very strong. I don't know about increased r7d and if it will significantly impact earnings.From yesterdays Roche release Behind the Numbers Roche's sales were boosted by its $10.2 billion takeover of Corange Ltd., which included German diagnostics company Boehringer Mannheim GmbH, analysts said. Still, growth excluding the acquisition was probably between 10 and 11 percent, or almost twice the expected industry average, according to analysts' estimates. Sales were also boosted by Viracept, an AIDS drug developed by Agouron Pharmaceuticals Inc. of the U.S. and marketed by Roche in Europe. According to Credit Suisse First Boston analysts, Viracept is the best-selling AIDS treatment of its kind (protease inhibitor) in Europe. Now lets see if memory serves me right Roche also sells a PI. Interesting that Viracept in an open market with large sales force and governments picking many of the drugs available ie the most cost effective therapy Viracept is the best selling PI in Europe where Roche calls home Regards Norden